| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
ARTICLES |
Department of Animal Sciences, Rutgers, State University of New Jersey (W.S.C., B.W., P.V.), New Brunswick, New Jersey 08901; and Department of Animal Sciences, Cornell University (Y.R.B.), Ithaca, New York 14853
Address all correspondence and requests for reprints to: Wendie S. Cohick, Ph.D., Rutgers, State University of New Jersey, 108 Foran Hall, 59 Dudley Road, New Brunswick, New Jersey 08901-8520. E-mail: cohick{at}aesop.rutgers.edu
Insulin-like growth factor I (IGF-I) is a potent mitogen for both normal and transformed mammary epithelial cells (MEC), and IGF-binding protein-3 (IGFBP-3) potentiates IGF-I action in these cells. The synthesis of IGFBP-3 is stimulated by both IGF-I and agents that increase intracellular cAMP (e.g. forskolin) in the bovine MEC line MAC-T. In addition, the combination of IGF-I and cAMP increases IGFBP-3 messenger RNA to a greater extent than does either treatment alone. The molecular mechanisms responsible for this regulation are not known and therefore represent the focus of this study. The half-life of IGFBP-3 messenger RNA in untreated MAC-T cells was determined to be 11 h. Exposure to IGF-I or forskolin increased the half-life to 27 and 101 h, respectively. Nuclear run-on assays indicated that IGFBP-3 transcription rates were increased 3.5 ± 0.83-fold (n = 4) in cells treated with a combination of IGF-I and forskolin. To further study this regulation, 1.1 kb of the 5'-flanking region of the IGFBP-3 promoter were fused to a promoterless reporter plasmid encoding luciferase. Transient transfection assays indicated that both IGF-I and forskolin alone produced small, but significant, increases in IGFBP-3 promoter activity of 1.57 ± 0.12 and 1.59 ± 0.08-fold (P < 0.01), respectively (mean ± SE; n = 7). However, the combination of IGF-I and forskolin increased IGFBP-3 promoter activity 2.25 ± 0.14-fold above control values (P < 0.01), suggesting that these factors activate discrete signaling pathways that act in concert to stimulate IGFBP-3 gene transcription. Deletion analysis indicated that promoter fragments containing as little as 267 bp upstream of the TATA box retained responsiveness to IGF-I and forskolin. This region contains a 200-bp sequence that is approximately 80% homologous between the murine and bovine promoters. It contains several conserved AP-2 and Sp1 consensus binding sequences that may be important for the effects of IGF-I and forskolin on IGFBP-3 promoter activity. In summary, these data indicate that IGF-I and cAMP, working through separate signaling pathways, activate both transcriptional and posttranscriptional mechanisms to stimulate IGFBP-3 synthesis in MEC.
This article has been cited by other articles:
 |
|
 |
|
  J. M Fleming, J. A Brandimarto, and W. S Cohick The mitogen-activated protein kinase pathway tonically inhibits both basal and IGF-I-stimulated IGF-binding protein-5 production in mammary epithelial cells J. Endocrinol., August 1, 2007; 194(2): 349 - 359. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. A. Samani, S. Yakar, D. LeRoith, and P. Brodt The Role of the IGF System in Cancer Growth and Metastasis: Overview and Recent Insights Endocr. Rev., February 1, 2007; 28(1): 20 - 47. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J M Fleming, B J Leibowitz, D E Kerr, and W S Cohick IGF-I differentially regulates IGF-binding protein expression in primary mammary fibroblasts and epithelial cells J. Endocrinol., July 1, 2005; 186(1): 165 - 178. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. Ongeri, M. F. Verderame, and J. M. Hammond Follicle-Stimulating Hormone Induction of Ovarian Insulin-Like Growth Factor-Binding Protein-3 Transcription Requires a TATA Box-Binding Protein and the Protein Kinase A and Phosphatidylinositol-3 Kinase Pathways Mol. Endocrinol., July 1, 2005; 19(7): 1837 - 1848. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Sivaprasad, J. Fleming, P. S. Verma, K. A. Hogan, G. Desury, and W. S. Cohick Stimulation of Insulin-Like Growth Factor (IGF) Binding Protein-3 Synthesis by IGF-I and Transforming Growth Factor-{alpha} Is Mediated by Both Phosphatidylinositol-3 Kinase and Mitogen-Activated Protein Kinase Pathways in Mammary Epithelial Cells Endocrinology, September 1, 2004; 145(9): 4213 - 4221. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Zhang and J. D. Veldhuis Requirement for Proximal Putative Sp1 and AP-2 cis-Deoxyribonucleic Acid Elements in Mediating Basal and Luteinizing Hormone- and Insulin-Dependent in Vitro Transcriptional Activation of the CYP17 Gene in Porcine Theca Cells Endocrinology, June 1, 2004; 145(6): 2760 - 2766. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. M. Ongeri, Q. Zhu, M. F. Verderame, and J. M. Hammond Insulin-Like Growth Factor-Binding Protein-3 in Porcine Ovarian Granulosa Cells: Gene Cloning, Promoter Mapping, and Follicle-Stimulating Hormone Regulation Endocrinology, April 1, 2004; 145(4): 1776 - 1785. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Ruiz, P. Troncoso, C. Bruns, and M. Bar-Eli Activator Protein 2{alpha} Transcription Factor Expression Is Associated with Luminal Differentiation and Is Lost in Prostate Cancer Clin. Cancer Res., December 1, 2001; 7(12): 4086 - 4095. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. E. Walker, E. M. Wilson, D. Powell, and Y. Oh Butyrate, a Histone Deacetylase Inhibitor, Activates the Human IGF Binding Protein-3 Promoter in Breast Cancer Cells: Molecular Mechanism Involves an Sp1/Sp3 Multiprotein Complex Endocrinology, September 1, 2001; 142(9): 3817 - 3827. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Wang, X. Ma, L.-C. C. Yeh, and M. L. Adamo Differential Regulation of IGF-Binding Protein Gene Expression by cAMP in Rat C6 Glioma Cells Endocrinology, September 1, 2001; 142(9): 3917 - 3925. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
